



National Securities Market Commission
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Colmenar Viejo (Madrid), January 28, 2019

Pursuant to Article 17 of Regulation (EU) n° 596/2014 on market abuse and Article 226 of the consolidated text of the Spanish Securities Market Act, approved by Royal Legislative Decree 4/2015, of 23 October, we hereby make the following **REGULATORY ANNOUNCEMENT**:

“Pharma Mar, S.A. has granted a mandate to Alantra Corporate Finance, S.A.U. for the sale of its stake in its subsidiary Zelnova Zeltia S.A., with the objective of maximizing the price of said sale.

As it was gathered in the merger project between Zeltia, S.A. and Pharma Mar, S.A. (relevant fact of May 19, 2015, with registration number 223,175), Pharma Mar, S.A. continues to develop its growth strategy in the oncology business.”